Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Takaaki Furukawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9746-6776; OpenAlex author ID A5039269495. Sources: OpenAlex.

Their work

Papers
34
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2020: 3 papers · 2021: 8 papers · 2022: 6 papers · 2023: 6 papers · 2024: 1 paper · 2025: 5 papers · 2026: 5 papers

Papers 34

  1. Endoscopic Retrograde Cholangiopancreatography-guided Biliary Drainage with Duckbill-type Anti-reflux Metal Stent versus Endoscopic Ultrasound-guided Hepaticog… Co-author DOI 10.1002/deo2.70154↗
  2. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1002/jhbp.70058↗
  3. Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinoteca… Co-author DOI 10.1093/jjco/hyaf194↗
  4. Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer. Co-author DOI 10.1159/000550483↗
  5. Patient-derived orthotopic xenograft models recapitulate the peritoneal dissemination of pancreatic cancer and delineate its transcriptional and regulatory pro… Co-author DOI 10.1186/s13046-026-03668-9↗
  6. Outcomes of multi-hole self-expandable metal stents versus fully covered self-expandable metal stents for malignant distal biliary obstruction in unresectable … Co-author DOI 10.1002/deo2.70014↗
  7. Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1007/s10147-025-02796-0↗
  8. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  9. Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.06.013↗
  10. Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status. Co-author DOI 10.2169/internalmedicine.3577-24↗
  11. Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyae028↗
  12. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… Co-author DOI 10.1002/deo2.205↗
  13. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… Co-author DOI 10.1007/s00464-022-09836-0↗
  14. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Co-author DOI 10.1016/j.pan.2023.02.002↗
  15. Outcomes of lung oligometastasis in pancreatic cancer. Co-author DOI 10.1093/jjco/hyad111↗
  16. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia. Co-author DOI 10.2169/internalmedicine.0730-22↗
  17. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic C… Co-author DOI 10.3390/cancers15020358↗
  18. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Co-author DOI 10.1016/j.pan.2022.04.003↗
  19. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1093/jjco/hyac145↗
  20. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0492-22↗
  21. Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8848-21↗
  22. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  23. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Co-author DOI 10.3390/ijms23031205↗
  24. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. Co-author DOI 10.1007/s10147-020-01827-2↗
  25. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-021-01912-0↗
  26. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗
  27. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Co-author DOI 10.1016/j.pan.2021.03.006↗
  28. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyaa247↗
  29. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyab014↗
  30. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyab091↗
  31. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancre… Co-author DOI 10.1097/mpa.0000000000001801↗
  32. Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor locatio… Co-author DOI 10.1016/j.pan.2020.07.004↗
  33. Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer. Co-author DOI 10.1055/a-1244-1989↗
  34. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. Co-author DOI 10.1186/s12885-020-06945-8↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masato Ozaka · 34 shared papers, 2020–2026 · strength 5.79
  2. Tsuyoshi Takeda · 33 shared papers, 2020–2026 · strength 5.60
  3. Takafumi Mie · 33 shared papers, 2020–2026 · strength 5.60
  4. Naoki Sasahira · 33 shared papers, 2020–2026 · strength 5.60
  5. Takashi Sasaki · 31 shared papers, 2020–2026 · strength 5.13
  6. Takeshi Okamoto · 24 shared papers, 2021–2026 · strength 4.50
  7. Akiyoshi Kasuga · 25 shared papers, 2020–2025 · strength 3.58
  8. Masato Matsuyama · 22 shared papers, 2020–2023 · strength 3.00
  9. Yuto Yamada · 16 shared papers, 2020–2023 · strength 2.14
  10. Hiroki Nakagawa · 6 shared papers, 2022–2025 · strength 1.05
  11. Yukari Suzuki · 4 shared papers, 2025–2026 · strength 1.01
  12. Yu Takahashi · 6 shared papers, 2020–2026 · strength 0.92
  13. Jun Hamada · 2 shared papers, 2026 · strength 0.53
  14. Yosuke Inoue · 3 shared papers, 2020–2026 · strength 0.52
  15. Manabu Takamatsu · 3 shared papers, 2021–2026 · strength 0.47
  16. Reo Maruyama · 1 shared paper, 2026 · strength 0.22
  17. Satoshi Kobayashi · 1 shared paper, 2025 · strength 0.19
  18. Shuichi Mitsunaga · 1 shared paper, 2025 · strength 0.19
  19. Yoshito Komatsu · 1 shared paper, 2025 · strength 0.19
  20. Taro Yamashita · 1 shared paper, 2025 · strength 0.19
  21. Mitsuhito Sasaki · 1 shared paper, 2025 · strength 0.19
  22. Masafumi Ikeda · 1 shared paper, 2025 · strength 0.19
  23. Naohiro Okano · 1 shared paper, 2025 · strength 0.19
  24. Hiroaki Nagano · 1 shared paper, 2025 · strength 0.19
  25. Hiroshi Imaoka · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.